인쇄하기
취소

Kim Myung-sook named Novartis's Sebivo EGM leader

Published: 2006-12-21 06:57:00
Updated: 2006-12-21 06:57:00
Novartis Korea said Kim Myung-sook, 37, a team leader of Novartis Korea' infection unit, was named a global crew leader (Head Center of Exellence) of Sebivo (telbivudine), a new hepatitis B virus (HBV) nucleoside analog polymerase inhibitor, in the emerging growth market (EGM).

Her EGM marketing leader nomination has been attributed to her outstanding marketing capability and to Novartis hea...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.